Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Encouraging Clinical Outcomes for Lymphoma Patients Participating in Early Phase Clinical Trials in the Current Era: A Single Institution and a Global Perspective

Jenny O'Nions, MBBChir, PhD MRCP, FRCPath, Anna Cowley, MBBS, BSc, MRCP, FRCPath, Hakim-Moulay Dehbi, PhD, Dima El-Sharkawi, MBBS BSc FRCPath MD, Shirley D'Sa, MD FRCP, FRCPath, Kirit M. Ardeshna, MA MDFRCP FRCPath, Rakesh Popat, MBBS, BSc, MRCP, FRCPath, PhD, William Townsend, MD FRCPath

Blood (2018) 132 (Supplement 1): 4227.

https://doi.org/10.1182/blood-2018-99-118497

Published: 2018

Journal Articles

Long Term Efficacy, Safety and PK/PD Profile of the Anti-C1s Antibody (BIVV009) in Primary Cold Agglutinin Disease Patients

Ulrich Jaeger, MD, Shirley D'Sa, MD FRCP, FRCPath, Christian Schoergenhofer, MD, Johann Bartko, MD, Christian Sillaber, MD, Petra Jilma-Stohlawetz, MD, Michael Fillitz, MD, Thomas Schenk, MD, Gary Patou, MD, Sandip Panicker, PhD, Graham C Parry, PhD, James C Gilbert, MD, Bernd Jilma, MD

Blood (2017) 130 (Supplement 1): 703.

https://doi.org/10.1182/blood.V130.Suppl_1.703.703

Published: 2017

Journal Articles

A Seven Gene Signature to Distinguish Bortezomib- and Lenalidomide-Responsive Myeloma: Rnaseq from the Padimac Study

Blood (2017) 130 (Supplement 1): 267.

https://doi.org/10.1182/blood.V130.Suppl_1.267.267

Published: 2017

Journal Articles

Outcomes of Stratification to ASCT or Not Based on Depth of Response: Results of a Phase 2 Trial Assessing the Impact of Minimal Residual Disease (MRD) in Multiple Myeloma Patients with Deferred ASCT (PADIMAC)

Blood (2017) 130 (Supplement 1): 1864.

https://doi.org/10.1182/blood.V130.Suppl_1.1864.1864

Published: 2017

Journal Articles

Whimsical (Waldenström's Macroglobulinemia Study Involving CArt-wheeL): Empowering Patients Internationally to Contribute Patient-Derived Data for Observational Research

Ibrahim Tohidi-Esfahani, B MD, Andrew Warden, Peter deNardis, Elena Malunis, Shirley D'Sa, MD FRCP, FRCPath, Marie Jose Kersten, MD PhD, Maria Lia Palomba, MD, Ruth Spearing, MD, Loic Ysebaert, MD PhD, Sheeba K. Thomas, MD, Constantine S. Tam, MBBS, MD FRACP, FRCPA, Clare Scott, MBBS PhDFRACP, Carl Harrington, Judith Trotman, FRACP

Blood (2017) 130 (Supplement 1): 1502.

https://doi.org/10.1182/blood.V130.Suppl_1.1502.1502

Published: 2017

Journal Articles

Whole Body (WB) MRI in Newly Diagnosed Multiple Myeloma (MM): Fat Fraction Changes at 8 Weeks Predict Response to Induction with Bortezomib Regimens

Arash Latifoltojar, MB BS, MSc, MPhil, Kwee L Yong, MBChB, PhD, Margaret Hall-Craggs, BA, MB BS, MD, Neil Rabin, MB,BS, PhD, Rakesh Popat, MBBS, PhD, Alan Bainbridge, Magdalena Sokolska, Nikolaos Dikaios, Shirley D'Sa, MD FRCP, FRCPath, Ali Rismani, MBBS, Shonit Punwani, Mb BS, BSc, PhD

Blood (2015) 126 (23): 1850.

https://doi.org/10.1182/blood.V126.23.1850.1850

Published: 2015

Journal Articles

Subcutaneous PAD As Induction Therapy for Patients with Newly Diagnosed Myeloma: A Phase 2 Trial Assessing the Impact of Minimal Residual Disease (MRD) in Patients with Deferred Autologous Stem Cell Transplantation (PADIMAC)

Blood (2014) 124 (21): 4745.

https://doi.org/10.1182/blood.V124.21.4745.4745

Published: 2014

NARROW

Encouraging Clinical Outcomes for Lymphoma Patients Participating in Early Phase Clinical Trials in the Current Era: A Single Institution and a Global Perspective

Long Term Efficacy, Safety and PK/PD Profile of the Anti-C1s Antibody (BIVV009) in Primary Cold Agglutinin Disease Patients

A Seven Gene Signature to Distinguish Bortezomib- and Lenalidomide-Responsive Myeloma: Rnaseq from the Padimac Study

Outcomes of Stratification to ASCT or Not Based on Depth of Response: Results of a Phase 2 Trial Assessing the Impact of Minimal Residual Disease (MRD) in Multiple Myeloma Patients with Deferred ASCT (PADIMAC)

Whimsical (Waldenström's Macroglobulinemia Study Involving CArt-wheeL): Empowering Patients Internationally to Contribute Patient-Derived Data for Observational Research

Whole Body (WB) MRI in Newly Diagnosed Multiple Myeloma (MM): Fat Fraction Changes at 8 Weeks Predict Response to Induction with Bortezomib Regimens

Subcutaneous PAD As Induction Therapy for Patients with Newly Diagnosed Myeloma: A Phase 2 Trial Assessing the Impact of Minimal Residual Disease (MRD) in Patients with Deferred Autologous Stem Cell Transplantation (PADIMAC)

Email alerts

ASH Publications

American Society of Hematology

Encouraging Clinical Outcomes for Lymphoma Patients Participating in Early Phase Clinical Trials in the Current Era: A Single Institution and a Global Perspective

Long Term Efficacy, Safety and PK/PD Profile of the Anti-C1s Antibody (BIVV009) in Primary Cold Agglutinin Disease Patients

A Seven Gene Signature to Distinguish Bortezomib- and Lenalidomide-Responsive Myeloma: Rnaseq from the Padimac Study

Outcomes of Stratification to ASCT or Not Based on Depth of Response: Results of a Phase 2 Trial Assessing the Impact of Minimal Residual Disease (MRD) in Multiple Myeloma Patients with Deferred ASCT (PADIMAC)

Whimsical (Waldenström's Macroglobulinemia Study Involving CArt-wheeL): Empowering Patients Internationally to Contribute Patient-Derived Data for Observational Research

Whole Body (WB) MRI in Newly Diagnosed Multiple Myeloma (MM): Fat Fraction Changes at 8 Weeks Predict Response to Induction with Bortezomib Regimens

Subcutaneous PAD As Induction Therapy for Patients with Newly Diagnosed Myeloma: A Phase 2 Trial Assessing the Impact of Minimal Residual Disease (MRD) in Patients with Deferred Autologous Stem Cell Transplantation (PADIMAC)

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only